19 Recruiting Studies Using Pacritinib

Active clinical trials that use this intervention, sourced directly from the NIH registry.

Browse by condition

Trials Using Pacritinib

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

📍 Mayo Clinic - Scottsdale — Scottsdale, Arizona

VEXAS

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

📍 University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center — Birmingham, Alabama

Primary Myelofibrosis

View Study & Checklist ➔

🟡 Not Yet Recruiting Phase1 💊 Investigational Drug / Biologic

Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms

📍 Roswell Park Comprehensive Cancer Center — Buffalo, New York

Myeloproliferative Neoplasm

View Study & Checklist ➔

🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

📍 The University of Kansas Cancer Center-Westwood — Westwood, Kansas

Myelofibrosis

View Study & Checklist ➔

🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic

Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

📍 Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin

Prostate Cancer

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

KSHV Inflammatory Cytokine Syndrome (KICS)

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

📍 Moffitt Cancer Center — Tampa, Florida

Leukemia, Myelomonocytic, Chronic

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

📍 City of Hope Medical Center — Duarte, California

Recurrent Mantle Cell Lymphoma

View Study & Checklist ➔

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Pacritinib in CMML

📍 The Mount Sinai Hospital — New York, New York

Chronic Myelomonocytic Leukemia

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

📍 Dana Farber Cancer Institute — Boston, Massachusetts

Waldenström Macroglobulinemia

View Study & Checklist ➔

🟢 Recruiting Early Phase1 💊 Investigational Drug / Biologic

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

📍 The University of Kansas Cancer Center — Fairway, Kansas

Myelofibrosis，MF

View Study & Checklist ➔

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Myelodysplastic Syndromes

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

📍 Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania

Primary Myelofibrosis

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

📍 City of Hope - Duarte Main Site — Duarte, California

Myelofibrosis

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington

Acute Myeloid Leukemia

View Study & Checklist ➔

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

📍 University of Miami — Miami, Florida

Graft vs Host Disease

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington

Accelerated Phase Myeloproliferative Neoplasm

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

📍 Washington University School of Medicine — St Louis, Missouri

E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

📍 City of Hope — Duarte, California

T-Cell Neoplasm

View Study & Checklist ➔